Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell R Smith

Showing results (1-10 of 129) with videos related to

Pageof 13
Sort By:
Expert Opinion on Pharmacotherapy|July 14, 2015
Ibrutinib in B lymphoid malignanciesMitchell R Smith
The Lancet. Oncology|December 15, 2015
Mature answers but new questions in indolent and mantle-cell lymphomaMitchell R Smith
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Antibodies and hematologic malignanciesMitchell R Smith
Current Opinion in Hematology|June 10, 2008
Mantle cell lymphoma: advances in biology and therapyMitchell R Smith
Future Oncology (London, England)|February 25, 2011
Should there be a standard therapy for mantle cell lymphoma?Mitchell R Smith
Blood|March 26, 2016
Ibrutinib: a force with a dark side?Mitchell R Smith
Oncogene|October 25, 2003
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceMitchell R Smith
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Is early hematopoietic stem-cell transplantation necessary in mantle-cell lymphoma?Mitchell R Smith
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 17, 2014
Allogeneic transplantation for lymphoma: risk-benefit balance is in the eye of the beholderMitchell R Smith
Discovery Medicine|July 4, 2013
Novel targeted therapies in peripheral T cell lymphomaDeepa Jagadeesh, Mitchell R Smith
Pageof 13

Showing results (1-10 of 129) with videos related to

Sort By:
Pageof 13
Expert Opinion on Pharmacotherapy|July 14, 2015
Ibrutinib in B lymphoid malignanciesMitchell R Smith
The Lancet. Oncology|December 15, 2015
Mature answers but new questions in indolent and mantle-cell lymphomaMitchell R Smith
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Antibodies and hematologic malignanciesMitchell R Smith
Current Opinion in Hematology|June 10, 2008
Mantle cell lymphoma: advances in biology and therapyMitchell R Smith
Future Oncology (London, England)|February 25, 2011
Should there be a standard therapy for mantle cell lymphoma?Mitchell R Smith
Blood|March 26, 2016
Ibrutinib: a force with a dark side?Mitchell R Smith
Oncogene|October 25, 2003
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceMitchell R Smith
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Is early hematopoietic stem-cell transplantation necessary in mantle-cell lymphoma?Mitchell R Smith
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 17, 2014
Allogeneic transplantation for lymphoma: risk-benefit balance is in the eye of the beholderMitchell R Smith
Discovery Medicine|July 4, 2013
Novel targeted therapies in peripheral T cell lymphomaDeepa Jagadeesh, Mitchell R Smith
Pageof 13